登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由中国人民解放军总医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06471738,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 4
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(4 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
ECOG ≤ 2
入选标准第 14 条
Any of the following cytopenias, due to lymphoma: Hemoglobin ≤ 10 g/dL, or Platelets ≤ 100 x 10\^9/L, or Absolute neutrophil count (ANC) < 1.5 x 10\^9/L;
入选标准第 10 条
Lactate dehydrogenase (LDH) > upper limit of normal (ULN) or beta (B)2 microglobulin > ULN;
入选标准第 12 条
ANC > 1.0 x 10\^9/L (for patients without bone marrow involvement by lymphoma)
入选标准第 15 条
Platelet count > 50 x 10\^9/L (for patients without bone marrow involvement by lymphoma)
入选标准第 16 条
Prothrombin time (PT)/international normal ratio (INR) < 1.5 x (upper limit of normal) ULN and partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) < 1.5 x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder). When treated with warfarin or other vitamin K antagonists, then INR ≤ 3.0)
入选标准第 17 条
Serum aspartate transaminase (AST) and alanine transaminase (ALT) < 3 x ULN
入选标准第 18 条
Creatinine clearance > 30 ml/min calculated by modified Cockcroft-Gault formula
入选标准第 19 条
Bilirubin < 1.5 x ULN unless bilirubin is due to Gilbert's syndrome, documented liver involvement with lymphoma, or of non-hepatic origin, in which case bilirubin should not exceed 3 g/dL
入选标准第 20 条
Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [B-hCG]) pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study
入选标准第 21 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);既往治疗;影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06471738,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
A diagnosis of follicular lymphoma (grades 1, 2, or 3a), untreated. Stage II, III, or IV disease. Able and willing to provide written informed consent and to comply with the study protocol. at least one measurable disease. Must be in need of therapy as evidenced by at least one of the following criteria: Presence of at least one B symptom: Fever (> 38 Celsius [C]) not due to infectious etiology, or Night sweats, or Weight loss > 10% in the past 6 months; Fatigue due to lymphoma; Splenomegaly (> 13 cm); Compression syndrome (ureteral, orbital, gastrointestinal); Any of the following cytopenias, due to lymphoma: Hemoglobin ≤ 10 g/dL, or Platelets ≤ 100 x 10\^9/L, or Absolute neutrophil count (ANC) < 1.5 x 10\^9/L; Pleural or peritoneal effusion; Lactate dehydrogenase (LDH) > upper limit of normal (ULN) or beta (B)2 microglobulin > ULN; Other lymphoma-mediated symptoms as determined by the treating physician. ECOG ≤ 2 ANC > 1.0 x 10\^9/L (for patients without bone marrow involvement by lymphoma) Platelet count > 50 x 10\^9/L (for patients without bone marrow involvement by lymphoma) Prothrombin time (PT)/international normal ratio (INR) < 1.5 x (upper limit of normal) ULN and partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) < 1.5 x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder). When treated with warfarin or other vitamin K antagonists, then INR ≤ 3.0) Serum aspartate transaminase (AST) and alanine transaminase (ALT) < 3 x ULN Creatinine clearance > 30 ml/min calculated by modified Cockcroft-Gault formula Bilirubin < 1.5 x ULN unless bilirubin is due to Gilbert's syndrome, documented liver involvement with lymphoma, or of non-hepatic origin, in which case bilirubin should not exceed 3 g/dL Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [B-hCG]) pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study排除标准:Exclusion Criteria:
Known active central nervous system lymphoma or leptomeningeal disease Follicular lymphoma with evidence of diffuse large B-cell transformation Grade 3b follicular lymphoma Any prior history of other malignancy besides follicular lymphoma History of severe allergic or anaphylactic reactions to monoclonal antibody therapy Patients who have undergone major surgery within 14 days The researchers believe that it is not advisable for the participant to take part in this trial.
引自 ClinicalTrials.gov, NCT06471738, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06471738,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。